Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 3/20 | 0.42 |
| ▸ | GGH | Q92820 | 2/20 | 0.41 |
| ▸ | CA2 | P00918 | 5/20 | 0.39 |
| ▸ | CA1 | P00915 | 3/20 | 0.39 |
| ▸ | CA4 | P22748 | 1/20 | 0.37 |
| ▸ | MME | P08473 | 5/20 | 0.34 |
| ▸ | LAP3 | P28838 | 2/20 | 0.33 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | ACE | P12821 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13720890 | 1.00 | TGFBR1 (0.42) | TGFBR1GGHCA2CA1CA4 | |
| SCHEMBL6848 | 0.98 | TGFBR1 (0.43) | TGFBR1GGHCA2CA1CA4 | |
| SCHEMBL6845 | 0.98 | TGFBR1 (0.43) | TGFBR1GGHCA2CA1CA4 | |
| SCHEMBL20798046 | 0.98 | TGFBR1 (0.43) | TGFBR1GGHCA2CA1CA4 | |
| SCHEMBL13720886 | 0.95 | TGFBR1 (0.42) | TGFBR1GGHCA2CA1CA4 | |
| SCHEMBL5654860 | 0.95 | TGFBR1 (0.42) | TGFBR1GGHCA2CA1CA4 | |
| SCHEMBL13720235 | 0.95 | TGFBR1 (0.42) | TGFBR1GGHCA2CA1CA4 | |
| Calcium SCHEMBL5654876 | 0.95 | TGFBR1 (0.42) | TGFBR1GGHCA2CA1CA4 | |
| SCHEMBL10496242 | 0.95 | TGFBR1 (0.42) | TGFBR1GGHCA2CA1CA4 | |
| Potassium SCHEMBL10496259 | 0.95 | TGFBR1 (0.42) | TGFBR1GGHCA2CA1CA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8765189-B2 | Organophosphorous and multivalent metal compound compositions and methods | Howmedica Osteonic Corp. (US) | 2014-07-01 | — | — | US | disclosed |
| US-20120288446-A1 | ORGANOPHOSPHOROUS & MULTIVALENT METAL COMPOUND COMPOSITIONS & METHODS | HOWMEDICA OSTEONICS CORP. | 2012-11-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120288446-A1 | ORGANOPHOSPHOROUS & MULTIVALENT METAL COMPOUND COMPOSITIONS & METHODS | PHOSPHO1, PSPH, PTMS | TGFBR1 3402/4885GGH 1370/4885CA2 490/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.